FdaApplication
NDA 200533
Identifiers
- fda_app_no: NDA200533
Properties
| Property | Value |
|---|---|
| applicant_name | COLLEGIUM PHARMACEUTICAL INC |
| application_type | NDA |
| approval_date | 2011-08-25 |
Revenue by product
NUCYNTA ER
| Period | Revenue |
|---|---|
| Q2 2026 | $18.5M |
| Q1 2026 | $19.7M |
| Q3 2025 | $22.8M |
| Q2 2025 | $39.9M |
| Q1 2025 | $39.4M |
| Q4 2024 | $17.5M |
| Q3 2024 | $19.8M |
| Q2 2024 | $19.3M |
| Q1 2024 | $19.2M |
| Q4 2023 | $19.7M |
| Q3 2023 | $22.6M |
| Q2 2023 | $19.2M |
| Q1 2023 | $21.1M |
| Q4 2022 | $18.9M |
| Q3 2022 | $17.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NUCYNTA ER | TAPENTADOL HYDROCHLORIDE | EQ 100MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| NUCYNTA ER | TAPENTADOL HYDROCHLORIDE | EQ 250MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| NUCYNTA ER | TAPENTADOL HYDROCHLORIDE | EQ 150MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| NUCYNTA ER | TAPENTADOL HYDROCHLORIDE | EQ 200MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| NUCYNTA ER | TAPENTADOL HYDROCHLORIDE | EQ 50MG BASE | TABLET, EXTENDED RELEASE;ORAL |
5 products